DT-diaphorase: a target for new anticancer drugs

Cancer Treatment Reviews
S DansonM Ranson

Abstract

DT-diaphorase (DTD) is an obligate two-electron reductase which bioactivates chemotherapeutic quinones. DTD levels are elevated in a number of tumour types, including non-small cell lung carcinoma, colorectal carcinoma, liver cancers and breast carcinomas, when compared to the surrounding normal tissue. The differential in DTD between tumour and normal tissue should allow targeted activation of chemotherapeutic quinones in the tumour whilst minimising normal tissue toxicity. The prototypical bioreductive drug is Mitomycin C (MMC) which is widely used in clinical practice. However, MMC is actually a relatively poor substrate for DTD and its metabolism is pH-dependent. Other bioreductive drugs have failed because of poor solubility and inability to surpass other agents in use. RH1, a novel diaziridinylbenzoquinone, is a more efficient substrate for DTD. It has been demonstrated to have anti-tumour effects both in vitro and in vivo and demonstrates a relationship between DTD expression levels and drug response. RH1 has recently entered a phase I clinical trial in solid tumours under the auspices of Cancer Research UK. Recent work has demonstrated that DTD is present in the nucleus and is associated with both p53 and the heat shock...Continue Reading

References

Feb 1, 1976·Proceedings of the Society for Experimental Biology and Medicine·N A SchorC E Dunlap
Aug 1, 1975·Archives of Biochemistry and Biophysics·P M Hollander, L Ernster
Mar 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·Y ZhangG H Posner
Apr 15, 1992·Biochemical Pharmacology·R J Riley, P Workman
Jan 1, 1990·Free Radical Research Communications·J ButlerB M Hoey
Mar 15, 1990·International Journal of Cancer. Journal International Du Cancer·J J Schlager, G Powis
Jan 1, 1985·Journal of Toxicology and Environmental Health·M S BergerM T Smith
Apr 5, 1988·Biochemistry·B M HoeyA J Swallow
Sep 1, 1980·Proceedings of the National Academy of Sciences of the United States of America·A M BensonP Talalay
Nov 1, 1982·Bioscience Reports·C EdlundG Dallner
May 1, 1980·The Biochemical Journal·Y H EdwardsD A Hopkinson
Oct 12, 1995·Biochemical Pharmacology·A Begleiter, M K Leith
Jun 15, 1994·Journal of the National Cancer Institute·J H SchellensJ Verweij
Sep 1, 1993·Archives of Biochemistry and Biophysics·S Alvarez, A Boveris
Apr 1, 1993·International Journal of Cancer. Journal International Du Cancer·M NishiyamaT Toge
Mar 15, 1996·International Journal of Cancer. Journal International Du Cancer·S V SinghH A Zaren
Mar 19, 1996·Proceedings of the National Academy of Sciences of the United States of America·R E BeyerG Lenaz
Jan 17, 1997·The Journal of Biological Chemistry·S ChenL M Amzel

❮ Previous
Next ❯

Citations

May 18, 2010·Cancer Chemotherapy and Pharmacology·Yongchuan GuWilliam R Wilson
Jan 5, 2012·International Journal of Colorectal Disease·Rui DingDaojun Chen
Apr 27, 2010·The Journal of Biological Chemistry·Ryan G SnodgrassChris A Pritsos
Jun 6, 2009·Antioxidants & Redox Signaling·Georg T Wondrak
Mar 8, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S J DansonM Ranson
Apr 6, 2006·Human Genomics·Vasilis VasiliouDaniel W Nebert
May 26, 2006·Radiation Oncology·Myrna CandelariaAlfonso Dueñas-Gonzalez
Jun 2, 2007·Chemical & Pharmaceutical Bulletin·Natthida WeerapreeyakulMasahiko Isaka
Jul 13, 2013·Chinese Journal of Cancer·Christopher P GuiseKe Ding
Mar 1, 2008·Toxicological and Environmental Chemistry·Antonio E Alegría, Pedro Sanchez-Cruz
Aug 16, 2014·Nitric Oxide : Biology and Chemistry·Kavita Sharma, Harinath Chakrapani
Feb 20, 2008·International Journal of Hyperthermia : the Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group·Chang W SongHeon Joo Park
Jul 28, 2009·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Cheng Hua HuangYuh-Ling Lin
Dec 3, 2015·Chemical Research in Toxicology·Aurimas StulpinasAudronė Valerija Kalvelytė
May 16, 2012·Biochimie·Emanuele S ScarpaTiziana Cacciamani
Jun 16, 2007·Organic & Biomolecular Chemistry·Ute MünchbergClaus Jacob
Dec 22, 2010·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·J Giftson SenapathyN Nalini
Mar 5, 2016·Organic Letters·Vinayak S KhodadeHarinath Chakrapani
Feb 13, 2010·Bioorganic & Medicinal Chemistry·Wen CaiMohammad Behforouz
Nov 26, 2015·Biochimica Et Biophysica Acta·Marija GerMindaugas Valius
Apr 28, 2009·Biochemical Pharmacology·Christopher M CabelloGeorg T Wondrak
Dec 20, 2008·BioFactors·Francesca BrugeGian Paolo Littarru
Jan 22, 2011·British Journal of Pharmacology·Moon-Taek ParkHeon Joo Park
Jul 10, 2014·The AAPS Journal·Irene GiangGregory M K Poon
May 26, 2015·Analytical Chemistry·Bijeta PrasaiRobin L McCarley
May 15, 2015·Chemical Communications : Chem Comm·Peilian LiuShuizhu Wu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis